Get started

Pennystock

Disposable Surgical Robotic Device - BIG News Coming 8/17/20Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using the Company’s LIBERTY Robotic System. finance.yahoo.com On 1/13/20, H.C. Wainwright maintained a Buy rating on MBOT and raised the price target from $12 to $26.00. I think this device could be a game changer. Disposable medical devices is where the future is going especially for sanitary reasons. Watch this stock Monday, 8/17/2020, it could run hard. I think the stock has been consolidating for a while and is coiling and ready to explode higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:MBOTLong
by HotCharts
Bullish Charts - Bitcoin Record Highs. Gold Record Highs. Launched in 2013, the BIT is sponsored by Alternative Currency Asset Management (ACAM), a wholly-owned subsidiary of SecondMarket Holdings, Inc. and an affiliate of SecondMarket, Inc. (custodian, marketing and distribution partner). ACAM has engaged leading service providers Ernst & Young (auditor). Chart looks like this one is going to $17 to $20 real soon. Daily Chart PMO is spiking up, Bullish Volume is Bullish RSI is Bullish MACD is Bullish Accumulation is Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
GLong
by HotCharts
Beat Earnings. Raised Guidance. No Debt. USA Protective GearAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. Net Sales of $25.5 Million, an Increase of 123.4% Year-over-Year Provides Update on Orders for Personal Protective Equipment (PPE) Net sales for the second quarter of 2020 were $25.5 million, compared to $11.4 million for the second quarter of 2019, up 123.4% year-over-year. Net income for the second quarter of 2020 was $6.2 million, or $0.46 per diluted share, compared to $1.0 million, or $0.08 per diluted share, for the second quarter of 2019, up 475% on a per share basis. NOGALES, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the three month period ended June 30, 2020. finance.yahoo.com Need I say anymore? Earnings blew past Wall Street Estimates. APT raised guidance and the company has no debt. Protective gear and N95 masks will be a part of the Worldwide dress code through 2020 and into 2021 even if a vaccine is approved because not everyone will want to take the vaccine shot. Today's sell off was outrageous and an early Christmas gift for anyone looking for a quality company that makes protective gear & N95 masks in the USA! Target: $32 Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
2
Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California. This morning Durect reported earrings that blew away Wall Street Estimates. Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate Sales more than doubled estimates. Daily Chart is Bullish Indicators are rising, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:DRRXLong
by HotCharts
Rapid Recovery Respiratory Failure - COVID-19 TreatmentRelief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland. RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol finance.yahoo.com I think this stock could spike like Moderna Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OTC:RLFTFLong
by HotCharts
1
Bullish Charts - Plasma Play, FDA Approved Plasma FacilitiesADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. BREAKING NEWS TODAY - 07/30/2020 ADMA Biologics shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients. www.benzinga.com On July 6, 20, ADMA opened a new plasma facility and is awaiting emergency authorization for a second location. finance.yahoo.com With the FDA asking for everyone to donate plasma, this stock could rip! Plasma stocks ripped today and continue to rip. This company already is up and running one plasma facility. Game On! Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ADMALong
by HotCharts
Avinger On High Alerts. (AVGR)We analyzed this one back in june to identify a massive falling wedge on this penny stock. We have kept it on our radar as it did breakout of the pattern and then retested the lows, treating the old Resistance a ps new support to create what looks to be a double bottom range support. This can be signs of accumulation to push price up. Horizontal levels are the breakout levels you will want to play and accumulate. Remember to diversify, especially on pennystocks
NASDAQ:AVGR
by UnknownUnicorn2319099
Bullish Charts - Coil, Pennant, Flag - Vans with DronesWorkhorse Group Inc. designs, manufactures, builds, sells, and leases battery-electric vehicles and aircraft in the United States. It operates through two divisions, Automotive and Aviation. The company also develops cloud-based and real-time telematics performance monitoring systems that enable fleet operators to optimize energy and route efficiency. Its products include electric cargo vans, and medium and light-duty pickup trucks, as well as HorseFly delivery drones systems. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Loveland, Ohio. Today, there was an article on Dow Jones talking about Workhorse Pairing Vans with Drones to Drive Deliveries. www.barrons.com On 07/24/20, there was another article, "Trucks of the Future." & "Electric Trucks are the Future." workhorse.com - Beautiful Electric Truck On 07/23/20, Workhorse reported a purchase order for 20, C-1000 Electric Delivery Trucks. On 07/21/20, Workhorse talks about supplying electric trucks to the Postal Service. Does the news get any better? Yes, on 07/14/20, Workhorse announces Ryder will now offer the C-1000 All-Electric Step Vans for rental locations. On the Daily Chart, it looks to me like it's flagging, Bullish To some, it might look like an uptrending coil or a Bullish Pennant. No matter how you look at the daily chart, it looks to me like a very Bullish setup. RSI is turning up, Bullish OBV is turning up, Bullish Stochastic is turning up, Bullish Accumulation is Bullish I see big things coming for this company! Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:WKHSLong
by HotCharts
Longterm Play For Sharp Corporation? (SHCAY)I've been watching this one for a while and am highly interested based off the technicals. We have been pretty stable in price action around the previous all time low, which also resulted in a large move to the upside. To me this looks like an accumulation play on a double bottom major support. I am accumulating for a very long term trade, with also buys eyed at the 2.30 lows for more accumulation. Pennystocks I like to do 1-3% of working capital in OTC markets.
OTC:SHCAY
by UnknownUnicorn2319099
1
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. DAILY CHART IS BULLISH OBV is Bullish MACD turned up Bullish RSi crossed center line and turned up, Bullish PMO is turning up, Bullish This little stock could spike hard. Best of luck everyone! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Bullish Charts - Robust Earnings, Undervalued & 7.79% YieldNavient Corporation provides education loan management and business processing solutions for education, healthcare, and government clients at the federal, state, and local levels in the United States. It operates through four segments: Federal Education Loans, Consumer Lending, Business Processing, and Other. The company holds and acquires Federal Family Education Loan Program loans that are insured or guaranteed by state or not-for-profit agencies; and performs servicing and asset recovery services on its own loan portfolio, and federal education loans owned by the United States Department of Education and other institutions. It also holds, originates, and acquires consumer loans; and performs servicing activities on its own education loan portfolio, including private education loans, and private education refinance loans. In addition, the company offers revenue cycle management and business processing services; and healthcare services that include revenue cycle outsourcing, accounts receivable management, extended business office support, and consulting engagement for federal, state, and municipal clients; public authorities; and healthcare organizations. Further, it provides customizable solutions for its clients that include hospitals, hospital systems, medical centers, large physician groups, and other healthcare providers; and corporate liquidity portfolio and debt repurchase services. The company was founded in 1973 and is headquartered in Wilmington, Delaware. 07/21/20, Navient Q2 Earnings Blew Away Wall Street Estimates Daily Chart looks Bullish with indicators turning up, positive. BULLISH The company has a current P/E of only 4.94x Current EPS: $1.54 Yield: 7.79% Reported Earnings: Q2 EPS $0.91 Beats $0.47 Estimate Market Cap: 1.5 Billion Institutional Ownership: 98.17% In my opinion, the stock is DIRT CHEAP at current levels. Compare this company's earnings to Bank of America & Wells Fargo, NAVI is blowing away Bank of America earnings along with many other large banks including Wells Fargo! I think NAVI should be trading around $30.00 all day long with the earnings the company is delivering. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:NAVILong
by HotCharts
2
CHEK Check-Cap upside potential - huge volume!Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. Net Income $-13,840,000, but an encouraging Quick Ratio of 3.69. Looking at the volume, this asset can double its price is seconds. on 5/28/2020 HC Wainwright Reiterated Chek Rating to Buy and the target is $2.00. Not trading advice. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:CHEKLong
by TopgOptions
Spotify Rumored Buyout of SONO - $4 Billion or more, Over $31Sonos, Inc., together with its subsidiaries, designs, develops, manufactures, and sells multi-room audio products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides wireless speakers, home theater speakers, components, and accessories. It offers its products through approximately 10,000 third-party retail stores, including custom installers of home audio systems; and e-commerce retailers, as well as through its Website sonos.com. The company was formerly known as Rincon Audio, Inc. and changed its name to Sonos, Inc. in May 2004. Sonos, Inc. was founded in 2002 and is headquartered in Santa Barbara, California. "We are hearing from a European desk (Spotify is based in Sweden) that Spotify is preparing a roughly $4 billion bid to acquire home entertainment company Sonos (over $31 per share). There has been talk of an interest by Apple in Sonos, but the Sonos board is prepared to go ahead with Spotify. Dont know stock/cash terms." Lets see what happens. Rumor SONO will be bought has been circulating for several months. Today's price action tells us something is brewing! Best of luck folks! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:SONOLong
by HotCharts
1
Bullish Charts - Vaccine Reduced COVID-19 into Common ColdAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. On 07/15/20, Researchers said AbbVie's Tricor reduced severity of COVID-19 into "NOTHING WORSE THAN A COLD." www.yahoo.com In my opinion, a vaccine doesn't get any better than this. AbbVie has the vaccine! Where is all the great news about Tricor killing COVID-19.??? If the stock can break through around $107, I think it's going to spike hard! The daily chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:ABBVLong
by HotCharts
NIO ES6 - Amazing Vehicle! - Watch This VideoJust an FYI for NIO shareholders. I thought you would be very interested in this video. I also think this vehicle is a Tesla killer. I think China will eventually shut out Tesla & NIO will take over the Chinese Electric Vehicle Market. www.youtube.com Again, after watching stocks like SOLO, SPCE, WKHS, SHLL, SPAQ, NKLA, NFYEF & AYRO trade at crazy multiples with nothing to show for it, I think NIO is DIRT CHEAP! In my opinion, NIO should be trading in the $50 to $100 range right now! NIO is years ahead of the competition. I think it will take other electric vehicle companies several years to catch NIO. Best of luck with your trades! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NIOLong
by HotCharts
Bullish Charts - Robust Earnings, Electric Vehicle TechnologiesGarrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. The company offers light vehicle gasoline and diesel, and commercial vehicle turbochargers. Its integrated vehicle health management tools detect intermittent faults and anomalies to provide understanding of the real-time health of a vehicle system. The company offers its products through distribution networks. Garrett Motion Inc. was incorporated in 2018 and is headquartered in Rolle, Switzerland. Daily Chart looks great! Volume, Bullish PMO, Bullish MACD, Bullish RSI, Bullish Stochastic, Bullish On Balance Trending Up, Bullish Accumulation Trending Up, Bullish It looks like the stock price broke out above the cloud at or around the $5.73 range. On 05/11/20, the company announced a huge spike in EPS. Q1 EPS $0.91, Sales $745.000 Million, Beat $664.040 Million Wall Street Estimates This one sentence sums up why the company is seeing a surge in revenue and earnings... "Garrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. " The electric vehicle industry is red hot! Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
GLong
by HotCharts
Penny Stock Indecision ! BRLL #otcpink #pennystocksAs you can see BRLL one hour chart rsi has hit 33 and this almost always means some nice upside will be coming - perhaps even 50% or more . But .... there's a problem . July is the one month I'm a bit cautious to but penny stocks - mid summer is notoriously dumpy - plus I'm not losing anything by sitting it out .Anyway it's also hit a TDSeq9 in red and should be good for at least 10% - I'll just be upset if it shoots up because I'm not jumping back into penny stocks til mid or late August !
OTC:BRLL
by shimmeringpath
1
KNOS ascending triangle. Huge Potential with Covid 2nd waveCurrently KNOS is in an ascending bull flag. Why KNOS has huge potential within the months to come: Their air filtration technology fully removes harmful allergens, bacteria, viruses (including the flu) and even gases from your breathing space. This product far outperforms the outdated 1940’s technology of a HEPA filter, and eliminates the shortcomings of any other air Kronos owns 12 patents in total, all focused on air filtration, and the removal of harmful bacteria, allergens and viruses from the breathing space. Patents: US 7,150,780 B2 US 6,937,455 B2 US 6,919,698 B2 US 6,727,657 B2 US 7,122,070 B1 US 6,963,479 B2 US 7,053,565 B2 US 6,664,741 B1 US 2010/0047115 A1 US 2009/0022340 A1 US 2010/0065510 A1 US 2010/0065510 A1 June 18th, 2020, Kronos signs deal to acquire US based leader in electronics manufacturing industry including its 85,000 square foot manufacturing facility. Kronos announced that it has signed a “Letter of Intent” with a privately held company to acquire a manufacturing facility for its consumer electronics products operations. The Company plans to manufacture a variety of electronic products, including medical ventilators and other vitally necessary medical equipment in addition to its flagship air purification products. Having their own manufacturing facility would not only help them to scale production to address growing sales and product line expansion, but also to develop new products and bring those to market much faster under a more efficient and controllable cost structure. June 29th, 2020 Kronos starts taking pre-orders for air purification products.
OTC:KNOSLong
by OttersOnly
3
Bullish Charts - Above the Cloud, Ready to Spike, Zika VirusBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Daily Chart: Volume: Bullish PMO Turning Up, Bullish MACD Turning Up, Bullish RSI: Bullish Stochastic: Bullish OBV: Bullish Accumulation: Bullish Sector: Bullish Closed above the cloud on Friday - Bullish On 06/10/2020, Company reported Galidesivir stopped the Zika virus replication. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:BCRXLong
by HotCharts